Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
JJ Castillo, RH Advani, AR Branagan… - The Lancet …, 2020 - thelancet.com
Waldenström macroglobulinaemia is an indolent B-cell lymphoma with clearly defined
criteria for diagnosis, initiation of therapy, and response, which was established by …
criteria for diagnosis, initiation of therapy, and response, which was established by …
Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies
SP Treon, L Xu, ML Guerrera, C Jimenez… - Journal of Clinical …, 2020 - ascopubs.org
Next-generation sequencing has revealed recurring somatic mutations in Waldenström
macroglobulinemia (WM), including MYD88 (95%-97%), CXCR4 (30%-40%), ARID1A …
macroglobulinemia (WM), including MYD88 (95%-97%), CXCR4 (30%-40%), ARID1A …
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management
MA Gertz - American journal of hematology, 2023 - Wiley Online Library
Abstract Disease Overview Waldenström macroglobulinemia (WM) is a lymphoplasmacytic
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
M Dimopoulos, RG Sanz, HP Lee, M Trneny… - Blood …, 2020 - ashpublications.org
Patients with Waldenström macroglobulinemia (WM) lacking activating mutations in the
MYD88 gene (MYD88 WT) have demonstrated relatively poor outcomes to ibrutinib …
MYD88 gene (MYD88 WT) have demonstrated relatively poor outcomes to ibrutinib …
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management
MA Gertz - American journal of hematology, 2021 - mayoclinic.elsevierpure.com
Abstract Disease Overview: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …
Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline
G Pratt, D El‐Sharkawi, J Kothari, S D'Sa… - British journal of …, 2022 - Wiley Online Library
Scope The objective of this guideline is to provide healthcare professionals with clear
guidance on the management of patients with Waldenström macroglobulinaemia. In …
guidance on the management of patients with Waldenström macroglobulinaemia. In …
Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization …
K Laribi, S Poulain, L Willems… - British Journal of …, 2019 - search.ebscohost.com
The article focuses on study that evaluated the efficacy and safety of bendamustine plus
rituximab (BR) in symptomatic untreated patients with Waldenstr€ om macroglobulinaemia …
rituximab (BR) in symptomatic untreated patients with Waldenstr€ om macroglobulinaemia …
Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology
SK Kumar, NS Callander, K Adekola… - Journal of the National …, 2024 - jnccn.org
The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL)
has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a …
has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a …
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes
JP Abeykoon, S Zanwar, SM Ansell… - British journal of …, 2020 - Wiley Online Library
Ibrutinib‐related data in Waldenström macroglobulinaemia (WM) remain sparse, particularly
outside of trials. We report on 80 patients [previously treated, n= 67 (84%), treatment‐naïve …
outside of trials. We report on 80 patients [previously treated, n= 67 (84%), treatment‐naïve …
Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management
MA Gertz - American journal of hematology, 2019 - Wiley Online Library
Disease Overview Waldenström macroglobulinemia (WM) is a lymphoplasmacytic
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …